Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLUCOSE-MGH
NCT06003153Phase 4Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2024
- Primary completion
- May 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Massachusetts General Hospital. Started Mar 2024; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06003153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003153.